SCHEMBL756717

SCHEMBL756717

NC([C]=O)CCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52133 1.00
Hydrochloric Acid SCHEMBL21820004 0.98 CYP2D6 (0.61)
Ammonia Solution, Strong SCHEMBL28439739 0.98 CYP2D6 (0.61)
Glutamic Acid SCHEMBL7821241 0.89 GRM8 (0.72)
Alanine SCHEMBL29050844 0.89 GABRP (0.54)
Aspartic Acid SCHEMBL7823074 0.86 GRM8 (0.55)
SCHEMBL10530673 0.86 ENPEP (0.52)
SCHEMBL11453652 0.86 ENPEP (0.52)
SCHEMBL61065 0.80
SCHEMBL887143 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US claimed
EP-1512397-B1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2014-10-08 EP claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 US claimed
US-7604797-B2 Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives BIOMECHANISMS INC. (US) 2009-10-20 US claimed
CN-114555127-A Method for preparing polyglutamated antifolates and use of compositions thereof L.E.A.F.控股集团公司 2022-05-27 CN disclosed
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US disclosed
EP-1512397-B1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2014-10-08 EP disclosed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP disclosed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO disclosed
EP-2429535-A2 COMPOSITIONS AND METHODS FOR TREATING BURNS Mindcake, LLC (US) 2012-03-21 EP disclosed
WO-2010123759-A2 COMPOSITIONS AND METHODS FOR TREATING BURNS HICKS TERRY LEE (US) 2010-10-28 WO disclosed
WO-2005087251-A1 COMPOSITIONS AND METHODS FOR INHIBITING ABNORMAL CELL GROWTH CLAWNOR, INC. (US) 2005-09-22 WO disclosed
US-20050209150-A1 Compositions and methods for inhibiting abnormal cell growth CLAWNOR, INC. 2005-09-22 US disclosed
WO-2005032470-A2 COMPOSITIONS AND METHODS FOR TREATING BURNS KOHI CORPORATION (US) 2005-04-14 WO disclosed
EP-1512397-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 EP disclosed
US-4863903-A RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1989-09-05 US disclosed
US-4719288-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1988-01-12 US disclosed
US-4613676-A PEPTIDES CIBA-GEIGY CORPORATION (US) 1986-09-23 US disclosed